Neoadjuvant chemotherapy versus upfront surgery for perihilar cholangiocarcinoma: a propensity score matching analysis
HPB · 2026
DOI: 10.1016/j.hpb.2026.01.011 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift HPB, 2026. Verfasst von Keita Sonoda und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Bile Duct Neoplasms, Klatskin Tumor, Hepatectomy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Neoadjuvant chemotherapy (NAC) may improve outcomes in perihilar cholangiocarcinoma (PHC); however, its efficacy compared with upfront surgery (US) for resectable PHC remains unclear. We compared survival and clinicopathological characteristics between NAC and US in patients with technically resectable PHC, using propensity score matching (PSM). METHODS: We retrospectively analyzed 261 patients with resectable PHC who underwent surgical treatment (2016-2024) across multiple institutions. Among them, 50 received NAC and 199 underwent US. The 38 patients receiving NAC were matched 1:1 with patients undergoing US using PSM. Overall survival (OS) and progression-free survival (PFS) were compared between groups. Pathological response to NAC and its association with chemotherapy doses were also evaluated. RESULTS: Before PSM, OS and PFS did not differ significantly between the US and NAC groups. After PSM, OS did not differ significantly between groups, but PFS was significantly longer in the NAC group, where patients with a therapeutic-effect grade ≥1b had better PFS than those with US. Grade ≥1b response was associated with receiving ≥7 NAC doses. DISCUSSION: NAC may improve PFS in selected patients with resectable PHC, especially those showing major pathological responses. Prospective studies should validate these findings and define optimal selection criteria and regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
- Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: yutaabe@keio.jp.
- Department of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, 1163 Hachioji, Tokyo 193-0998, Japan.
- Department of Surgery, Saiseikai Yokohamashi Tobu Hospital, 3-6-1 Shimosuekichi, Tsurumi-ku, Yokohama-shi, Kanagawa 230-8765, Japan.
- Department of Surgery, Kawasaki Municipal Hospital, 21-1 Shinkawadori, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-0013, Japan.
- Department of Surgery, National Hospital Organization Saitama Hospital, 2-1 Suwa, Wako-shi, Saitama 351-0102, Japan.
Zitieren
APA
Sonoda, K., Abe, Y., Chiba, N., Nishiyama, R., Mihara, K., Hayatsu, S., Takano, K., Takemura, R., Kitago, M., Hasegawa, Y., Hori, S., Tanaka, M., Mishima, K., Nakano, Y., Kawachi, S., & Kitagawa, Y. (2026). Neoadjuvant chemotherapy versus upfront surgery for perihilar cholangiocarcinoma: a propensity score matching analysis. HPB. https://doi.org/10.1016/j.hpb.2026.01.011
Vancouver
Sonoda K, Abe Y, Chiba N, Nishiyama R, Mihara K, Hayatsu S, et al. Neoadjuvant chemotherapy versus upfront surgery for perihilar cholangiocarcinoma: a propensity score matching analysis. HPB. 2026. doi:10.1016/j.hpb.2026.01.011
BibTeX
@article{Sonoda2026,
author = {Sonoda, Keita and Abe, Yuta and Chiba, Naokazu and Nishiyama, Ryo and Mihara, Kisyo and Hayatsu, Shigeo and Takano, Kiminori and Takemura, Ryo and Kitago, Minoru and Hasegawa, Yasushi and Hori, Shutaro and Tanaka, Masayuki and Mishima, Kohei and Nakano, Yutaka and Kawachi, Shigeyuki and Kitagawa, Yuko},
title = {Neoadjuvant chemotherapy versus upfront surgery for perihilar cholangiocarcinoma: a propensity score matching analysis},
journal = {HPB},
year = {2026},
doi = {10.1016/j.hpb.2026.01.011}
}
EUVIMED